Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement to Support the Development of a New Therapeutic Approach in Inflammatory Bowel Disease (IBD)
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today a R&D collaboration agreement with the Crohn’s & Colitis Foundation to support the development of a new therapeutic approach in IBD. The Crohn’s & Colitis Foundation is one of world’s largest and most influential non-profit organization dedicated to finding cures for Crohn’s disease and ulcerative colitis.
The objective of the R&D collaboration is to confirm the relationship between the activation of the TREM-1 pathway and the severity and progression of IBD in patients, with the ultimate intention of developing a new treatment. Inotrem will conduct this project in partnership with the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai in New York. Under the terms of the agreement, Inotrem will access data and bio-samples from Foundation’s IBD Plexus®, which is the largest IBD database in the US with data from over 25,000 patients. The project is expected to last 18 months and will be a cornerstone in the design of Inotrem’s new drug candidate first-in-human clinical study.
There are today 10 million people worldwide suffering from IBD (Crohn’s disease and ulcerative colitis), a lifelong illness for which the medical need continues to be important despite improvement over the last 30 years. Approximately 30% of patients are primarily unresponsive to existing therapies and even among responders, up to 10% will lose their response to the drug every year.
For a decade, Inotrem has been pioneering the biology of TREM-1 as a regulator of the immune response in acute and chronic inflammatory diseases. TREM-1 has been reported as a likely contributor to IBD pathophysiology, and targeting this biological pathway could offer a new treatment option for IBD patients with immune dysregulation.
Sven Zimmermann, CEO of Inotrem, says: “We are looking forward to collaborating with such a recognized and well-respected organization as The Crohn’s & Colitis Foundation. The robustness and diversity of their IBD patient database is unparalleled and will allow for in-depth analysis of TREM-1 potential as a therapeutic target in IBD patients. This agreement marks the beginning a long and fruitful partnership”.
“We are dedicated to finding cures for Crohn’s disease and ulcerative colitis and improving the quality of life for those affected by these diseases,” said Dr. Caren Heller, Chief Scientific Officer for the Crohn’s & Colitis Foundation. “We are pleased to work with Inotrem, a company that has developed a strong scientific leadership around the TREM-1 pathway, and look forward to understanding the potential ways that the TREM-1 pathway may play a role in the treatment of inflammatory bowel disease.”
Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction. In parallel, Inotrem has also launched another program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media contact for Inotrem
Strategies & Image (S&I)
+33 6 03 35 92 05
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Align Announces Additional Leadership for UK and EMEA to Support Continued Growth18.5.2022 17:11:00 CEST | Press release
Align, the premier global provider of technology infrastructure solutions celebrates significant growth throughout the UK and EMEA markets with management changes to support increasing demand. The appointment of Giulia Marcolina as Managing Director and Mike Konold as AV Solutions Director of Align’s UK-based headquarters, will enable the team to deliver innovative collaborative technology and state-of-the-art AV solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005833/en/ Giulia Marcolina, a 15 year veteran with Align, is named Managing Director of Align's UK-based headquarters. (Photo: Business Wire) Giulia brings over 25 years of IT experience, previously serving as Align’s Programme Manager, delivering corporate office relocation and consolidation projects for clients such as Blackrock, Total Gas and Power, and UBS. In her new role, she will lead Align’s team of project managers in building upon Align’s lon
RMS Advances Climate Risk Modeling and Moves More Models to High Definition18.5.2022 16:30:00 CEST | Press release
RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, today announces it will be releasing four new High Definition™ (HD) models, including Europe Windstorm, North America Winterstorm (WT), North America Severe Convective Storm (SCS), and Terrorism. RMS HD Models represent the next generation of risk modeling, delivering deeper analysis and granularity from Moody’s. The HD probabilistic models incorporate a high-fidelity, simulation-based framework for modeling event frequency and severity, to provide a major step forward in the quality of catastrophe risk quantification. The framework allows for event footprints to be represented more realistically across larger event sets. The new RMS Europe Windstorm HD Model further enhances the current model and will cover 17 countries, adding Finland and Lichtenstein. The HD model includes a climate variability view and has expanded storm surge analytics to include the U.K., Ireland, France, and Belgium. Storm c
Suketu Upadhyay Elected to Vertex Board of Directors18.5.2022 16:30:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyayhas been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. “We are delighted to have Suky join the Vertex Board. His extensive financial and strategic experience in health care, paired with his leadership and expertise across biopharma and medtech, make him a valuable addition to our board of directors,” said Reshma Kewalramani, M.D., Vertex’s Chief Executive Officer and President. “It’s an honor to join Vertex, a company focused on serial innovation with an
Armory Makes Continuous Deployment Achievable and Effortless, at any Scale, for all Developers18.5.2022 16:17:00 CEST | Press release
Armory, the Continuous Deployment company empowering development teams to easily, reliably, safely, and continuously deploy software at any scale, today announced public early access to their new Continuous Deployment-as-a-Service product. Armory Continuous Deployment-as-a-Service delivers declarative deployments, across multiple environments, that support advanced strategies, so developers can focus on building great code rather than deploying it. “We believe deploying software continuously, at any scale, should be achievable and effortless for all developers of the world, not just the likes of Google and Netflix,” said Jim Douglas, President and CEO, Armory. “It’s our vision and mission to unlock innovation through software to make software continuous, scalable, secure, and safe, so developers can improve and protect their customers’ experience with confidence and ease.” To effectively compete in a software-defined world, development teams must ensure a stellar customer experience. S
Sermo Survey Reveals New Lung & Breast Cancer Research Rated as Most Interesting by Oncologists Attending ASCO This Year18.5.2022 15:15:00 CEST | Press release
A new survey from Sermo, a physician-first online community and leader in global HCP insights, timed to the annual American Society of Clinical Oncology (ASCO) conference found that nearly half (47%) of attending oncologists are most interested in new data being presented about lung cancer. This is followed by a similarly high interest in new data about breast cancer, as reported by 44% of oncologists surveyed. Additionally, oncologists/hematologists reported they are most excited about learning about tumor targeting antibodies treatments as reported by 54% of those surveyed. Ahead of ASCO’s Annual Meeting, new cancer research and innovations are the driving reason surveyed oncologists/hematologists are attending the conference this year (59%). However, how they plan to attend looks different to many oncologists, as only 18% of oncologists/hematologists surveyed said they will attend ASCO in-person this year. A Look Into the Pandemic’s Negative Impacts on Cancer Care Globally Oncologis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom